Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rebastinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 7/20 | 1.00 |
| ▸ | BRAF | P15056 | 8/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 7/20 | 1.00 |
| ▸ | SRC | P12931 | 3/20 | 1.00 |
| ▸ | RIPK1 | Q13546 | 2/20 | 1.00 |
| ▸ | AXL | P30530 | 2/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | ACOX3 | O15254 | 1/20 | 1.00 |
| ▸ | MAP3K7 | O43318 | 1/20 | 1.00 |
| ▸ | DYRK3 | O43781 | 1/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 1.00 |
| ▸ | ERN1 | O75460 | 1/20 | 1.00 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | RAF1 | P04049 | 1/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | CDK1 | P06493 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rebastinib SCHEMBL29354367 | 1.00 | BRAF (1.00) | BRAFABL1MAPK14SRCRIPK1 | |
| Rebastinib SCHEMBL29733447 | 1.00 | BRAF (1.00) | BRAFABL1MAPK14SRCRIPK1 | |
| Rebastinib SCHEMBL2034290 | 1.00 | BRAF (1.00) | BRAFABL1MAPK14SRCRIPK1 | |
| Rebastinib SCHEMBL2026623 | 0.99 | BRAF (0.99) | BRAFABL1MAPK14SRCRIPK1 | |
| Rebastinib SCHEMBL29733460 | 0.99 | BRAF (0.99) | BRAFABL1MAPK14SRCRIPK1 | |
| Rebastinib SCHEMBL12079461 | 0.95 | BRAF (0.91) | BRAFABL1MAPK14SRCRIPK1 | |
| SCHEMBL2024402 | 0.94 | BRAF (0.89) | BRAFABL1MAPK14SRCRIPK1 | |
| SCHEMBL20033385 | 0.94 | MAPK14 (0.89) | BRAFABL1MAPK14SRCRIPK1 | |
| SCHEMBL18814248 | 0.94 | MAPK14 (0.88) | BRAFABL1MAPK14SRCRIPK1 | |
| Rebastinib SCHEMBL16704166 | 0.94 | BRAF (0.88) | BRAFABL1MAPK14SRCRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680212-A1 | ADAR1 INHIBITORS FOR TREATING CANCER | Institute of Cancer Research Royal Cancer Hospital (GB) | 2026-01-21 | — | — | EP | disclosed |
| WO-2024189433-A1 | ADAR1 INHIBITORS FOR TREATING CANCER | INSTITUE OF CANCER RESEARCH ROYAL CANCER HOSPITAL (GB) | 2024-09-19 | — | — | WO | disclosed |
| US-20240263135-A1 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | FATE THERAPEUTICS, INC. | 2024-08-08 | — | — | US | disclosed |
| EP-3284481-B1 | CELL DEATH INDUCING AGENT FOR CELLS HAVING BRAF GENE MUTATION, AGENT FOR INHIBITING PROLIFERATION OF SAID CELLS AND PHARMACEUTICAL COMPOSITION FOR TREATING PATIENT SUFFERING FROM EFFECTS OF ABNORMAL PROLIFERATION OF SAID CELLS | NITTO DENKO CORP (JP) | 2024-05-15 | — | — | EP | disclosed |
| US-11932870-B2 | Compositions and methods for immune cell modulation in adoptive immunotherapies | FATE THERAPEUTICS, INC. | 2024-03-19 | — | — | US | disclosed |
| CN-114656470-B | Substituted quinazoline compound and preparation method and application thereof | 辽宁大学 | 2023-11-10 | — | — | CN | disclosed |
| CN-116271056-A | Cell death inducing agent for cell having BRAF gene mutation, proliferation inhibiting agent for the cell, and pharmaceutical composition for treating disease caused by abnormal proliferation of the cell | 日东电工株式会社 | 2023-06-23 | — | — | CN | disclosed |